Pharma Focus Asia

FUJIFILM Diosynth Biotechnologies Opens New Biopharmaceutical CDMO Facility In North America

Introduction:

FUJIFILM Diosynth Biotechnologies plans for the construction of largest cell culture biophramaceutical CDMO facility. The facility will be located in North America.

Features:

The new, state-of-the-art facility consists of large-scale cell culture manufacturing of bulk drug substance production with 8 x 20,000L bioreactors.

This facility having the potential to expand will add further 24 x 20,000L bioreactors. Moreover, it expands and further add  24 x 20,000L bioreactors.

The new biopharmaceutical facility also consists of automated fill-finish, commercial-scale, packaging and labelling services. In addition, the new facility will have the ability to produce life-impacting medicines.

The new facility is expected to be completed and fully opeartional by spring 2025. Once the construction is completed it is expected to create 725 new jobs.

Specifications:

NameFUJIFILM Diosynth Biotechnologies
TypeNew Construction
Year2025
magazine-slider-imageCytiva - Supor Prime filtersMFA + MMA 20244th Annual Cleaning Validation 20242nd Annual Pharma Impurity Conclave 2024CPHI Korea 2024CHEMICAL INDONESIA 2024World Orphan Drug Congress Europe 2024INALAB 2024Thermo Fisher - Drug Discovery and the impact of mAbsAdvanced Therapies USA 2024ISPE Singapore Affiliate Conference & Exhibition 20242024 PDA Aseptic Manufacturing Excellence Conference2024 PDA Aseptic Processing of Biopharmaceuticals Conference